CG Oncology, Inc.

CG Oncology to host a conference call on Dec. 5 to discuss Phase 3 BOND-003 trial results of cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC, featuring Dr. Mark Tyson. Cretostimogene is an investigational oncolytic immunotherapy for NMIBC, with trials including BOND-003 and PIVOT-006. CG Oncology aims to develop bladder-sparing therapies for bladder cancer patients.

CG Oncology to host conference call and webcast on December 5, 2024, at 7 am CST to discuss Phase 3 BOND-003 trial results of cretostimogene monotherapy in high-risk BCG-unresponsive NMIBC. Dr. Mark Tyson, II will present the results at the SUO 25th Annual Meeting in Dallas at 11:45 am CST. The webcast will be accessible via the company's Investor Relations website.

CG Oncology published Phase 1b study results in Nature Medicine, showing cretostimogene grenadenorepvec combined with nivolumab in muscle-invasive bladder cancer (MIBC) has a 42.1% pathologic complete response rate and 70.4% 1-year recurrence-free survival, with no dose-limiting toxicity or grade 3+ TRAEs. Cretostimogene's dual mechanism of action supports its potential as a bladder-sparing therapeutic for bladder cancer.

John McAdory, VP of ClinOPs at CG Oncology, uses Six Sigma skills to streamline clinical trial processes, focusing on reducing redundancy in study startup and feasibility questionnaires, aiming to cut costs and save time.

Dan Schell attended Veeva's R&D and Quality summit in Boston, finding it informative with valuable networking and insights on clinical trial challenges, eCOA readiness, and site data issues. He also met fellow editors, broadening his professional connections.

Foresite Capital closes $900M fund for novel therapeutics and biotech. Marea Therapeutics raises $190M for cholesterol-lowering monoclonal antibody. Santa Ana Bio secures $168M for autoimmune and inflammatory disease treatments. Bright Peak Therapeutics raises $107M for therapeutic cytokine synthesis. Alzheon raises $100M for Alzheimer’s Phase 3 program. Amber Therapeutics closes $100M Series A for neuromodulation therapy for urinary incontinence. iOnctura secures $85.8M for uveal melanoma treatment. Elion Therapeutics raises $81M for invasive fungal infections. Vilya announces $71M Series A for computational drug design. Moleculent AB closes $26M Series A for functional biology platform. Canary Speech secures $13M for AI-powered vocal biomarker technology. Fuse Diagnostics raises $2M for point-of-need pathogen diagnostics. Nuclera awarded $1.4M for eProtein discovery system.